CG Oncology, Inc. (CGON) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-02-27

How it makes money

It targets the 150,000-patient NMIBC market by positioning cretostimogene as a bladder-sparing alternative for patients who would otherwise undergo radical cystectomy.

The company focuses on a potential addressable population of 150,000 patients with non-muscle invasive bladder cancer (NMIBC). It specifically targets 25,000 patients who are unresponsive to the standard Bacillus Calmette-Guérin (BCG) therapy and 50,000 with intermediate-risk disease.

Earnings depend on the clinical adoption of cretostimogene as a "backbone" therapy. Because it is administered intravesically (directly into the bladder) in a manner similar to standard BCG, it integrates into existing urology workflows without requiring anesthesia or specialized medical oncology facilities.

What protects it: the moat

Management claims cretostimogene offers a best-in-disease profile, demonstrated by a 75.5% complete response rate and a simple intravesical route of administration.

The company asserts a competitive advantage based on durable efficacy and a favorable safety profile compared to existing systemic therapies. Phase 3 data showed no patients discontinued treatment due to related adverse events, and 97.3% of patients completed the full treatment course.

The product candidate holds FDA Fast Track and Breakthrough Therapy designations. Its intravesical delivery mechanism protects its market position by aligning with the economic and procedural preferences of community urology practices, unlike systemic alternatives that require infusion by medical oncologists.

What growth costs

It incurred $161.0 million in 2025 net losses while establishing a $25.0 million note to secure critical manufacturing assets for its clinical supply.

Reinvestment is concentrated on late-stage clinical trials, including the BOND-003 and PIVOT-006 registrational programs. The company expects these losses to increase substantially as it builds a commercial organization for its planned 2026 Biologics License Application completion.

To manage supply chain risk, the company took the unusual step of funding a $25.0 million note to enable a specific entity, Biovire, to acquire the manufacturing assets necessary to produce cretostimogene. It subsequently consolidated Biovire after obtaining control through a conversion event.

What could damage it

A clinical failure or regulatory rejection of cretostimogene would permanently impair the business because it currently has no other product candidates in development.

The company’s survival is tied exclusively to the success of a single engineered adenovirus. There are no secondary candidates or revenue-generating assets to buffer against a failed Biologics License Application or safety issues specific to the novel oncolytic viral class.

Regulatory delay is a significant threat, as the FDA has approved very few viral immunotherapies to date. This novel class requires specialized safety and contagion procedures that could prolong the review process or impose restrictive post-approval requirements.

About CG Oncology, Inc.

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.

Other companies in Biotechnology